TY - JOUR T1 - Effects of Digesti’Vas, Apolyherbal Formulation on Gastrointestinal-Related Measurements in Rodent Models AU - Shivalinge Gowda, K.P. AU - Nishar Banu, S. Ume AU - Mondal, Abhishek AU - Abhishek, K. AU - Samhitha, J. AU - Tejani-Butt, Shanaz AU - Loganayaki, Nataraj AU - Khader Shareef, K.S. AU - Venkateswarlu, K. JO - Research Journal of Pharmacology VL - 14 IS - 3 SP - 33 EP - 37 PY - 2020 DA - 2001/08/19 SN - 1815-9362 DO - rjpharm.2020.33.37 UR - https://makhillpublications.co/view-article.php?doi=rjpharm.2020.33.37 KW - gastrointestinal motility KW -Digesti’Vas KW -Appetite KW -loperamide KW -SGOT AB - The present study evaluated the activity of Digesti’Vas on gastrointestinal motility, appetite and hepatoprotective effects in a rodent model. Digesti’Vas is a polyherbal formulation developed by Suguna Foods Pvt Ltd. Acute toxicity and gastrointestinal motility activity were evaluated in mice. Appetite activity and potential hepatoprotective effects were evaluated in rats. Since, Digesti’Vas did not exhibit acute toxicity when given orally up to a concentration of 2000 mg kg–1 bw, 200 m kg–1 body wt. (1/10th of 2000 mg kg–1) was selected as the median dose. Digesti’Vas showed a significant increase in mean defecation period (346.2±65.83 min), comparable to the positive control, loperamide (383.0±37.83 min) in comparison to the normal control group (251.2±60.32 min). Digesti’Vas treatment also led to a significant increase in the percentage change in body weight (8.367±3.021 g) when compared to the normal control group (3.618±2.088 g) and a significant increase in percentage change in food intake (13.28±3.673 g) when compared to the normal control group (8.657±2.160 g). When measurements were done on various liver parameters, it was found that Digesti’Vas treated animals showed a significant decrease in serum ALP levels (401.8±10.04 U L–1) compared to CCl4 treated animals (493.2±108.4 U L–1); comparable to the positive control, Silymarin (370.5±37.82 U L–1). Digesti’vas significantly decreased serum SGPT levels (57.03±66.01 U L–1), compared to CCl4 treated animals (420.8±214.1 U L–1); in agreement with levels seen in Silymarin treated animals (61.39±37.87 U L–1). Furthermore, Digesti’Vas significantly decreased SGOT (6.953±3.712 U L–1) levels compared to the CCl4 treated group (29.65±5.765 U L–1), in keeping with levels seen after treatment with Silymarin (10.71±6.135 U L–1). This study suggests that Digesti’Vas, a herbal preparation that is formulated by Suguna Foods Pvt Ltd., possesses antimotility, hepatoprotective and increased appetite effects in a rodent model. Future studies investing the role of Digesti’Vas in alleviating gastrointestinal disorders are certainly warranted. ER -